Here are the important dates impacting CSL shares this year

Here's when CSL will announce its dividends and release its financial reports to the market.

| More on:
two young boys dressed in business attire and wearing spectacles sit side by side and watch closely an old fashioned television box receiver with built in wire ariels.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are trading at $280.30 on Tuesday, up 0.11% at the time of writing.

The ASX 200 healthcare giant is among many listed companies that have released their corporate calendars for 2025.

Let's review the important dates for CSL investors in the new year.

Key dates for CSL investors in 2025

The CSL share price is more likely to move on days when the company announces big news.

The first important date is less than a month away.

On 11 February, CSL will release its FY25 half-year results and announce its interim dividend.

The ex-dividend date for the interim CSL dividend will be 10 March.

The record date will be 11 March and the dividend will be paid to investors on 9 April.

CSL will announce its FY25 full-year results and final dividend on 19 August.

The ex-dividend date for the final dividend will be 9 September.

The record date will be 10 September and CSL will pay its shareholders on 3 October.

CSL will hold its annual general meeting on 28 October.

What happened to the CSL share price in 2024?

The CSL share price underperformed the benchmark S&P/ASX 200 Index (ASX: XJO) last year.

CSL shares ended 2024 1.77% lower while the ASX 200 gained 7.49% over the 12-month period.

The stock started the year at $286.65 per share and rose to a 52-week high of $313.55 in July.

But it could not sustain this growth.

The decline began after the company released its FY24 results in August.

CSL reported an 11% year-over-year revenue bump (in constant currency) to US$14.8 billion.

Net profit after tax before amortisation (NPATA) in constant currency was 15% higher at US$3.01 billion.

This flowed through to a 12% increase in the annual dividend payment.

Investors were not impressed, and the CSL share price began its painful second-half fall.

The CSL share price was volatile in the final six months of 2024 and eventually ended the year in the red.

Are CSL shares a buy?

As one of Australia's biggest listed companies, CSL receives a lot of broker coverage.

There is a very positive feeling on CSL shares, with many top brokers rating the stock a buy.

Bell Potter has a buy rating on the ASX 200 biotech with a 12-month share price target of $345.

The broker points out that CSL is trading on a 12-month forward price-to-earnings (P/E) ratio of 28x.

This is lower than its 10-year average of 31x.

Macquarie has an outperform rating on CSL and a $334 price target.

Jarden also has an overweight rating on the stock with a price target of $329.62.

Morgans has an add rating on CSL with a $330.75 price target.

UBS has a buy rating and also tips the CSL share price will lift to about $330 by the end of 2025.

Motley Fool contributor Bronwyn Allen has positions in CSL and Macquarie. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL and Macquarie. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

$1,000 invested in Mesoblast shares at the start of 2024 is now worth…

Did this biotech company deliver the goods for investors? Let's see what a $1,000 investment would be worth.

Read more »